Augmedix (NASDAQ:AUGX – Get Free Report) was upgraded by analysts at Evercore ISI from an “in-line” rating to an “outperform” rating in a report issued on Tuesday, Benzinga reports. The firm presently has a $5.00 price objective on the stock, up from their previous price objective of $4.50. Evercore ISI’s target price indicates a potential […]
Augmedix (NASDAQ:AUGX – Get Free Report) was upgraded by analysts at Evercore ISI from an “in-line” rating to an “outperform” rating in a report issued on Tuesday, Benzinga reports. The firm presently has a $5.00 price objective on the stock, up from their previous price objective of $4.50. Evercore ISI’s target price indicates a potential […]
Augmedix (NASDAQ:AUGX – Get Free Report) was upgraded by investment analysts at Evercore ISI from an “in-line” rating to an “outperform” rating in a research report issued on Tuesday, Benzinga reports. The brokerage presently has a $5.00 target price on the stock, up from their previous target price of $4.50. Evercore ISI’s price objective indicates […]
B. Riley initiated coverage on shares of Augmedix (NASDAQ:AUGX – Free Report) in a report issued on Wednesday morning, Marketbeat reports. The firm issued a buy rating and a $5.50 target price on the stock. B. Riley also issued estimates for Augmedix’s Q1 2024 earnings at ($0.12) EPS, Q2 2024 earnings at ($0.13) EPS, Q3 […]